ClinicalTrials.gg
Active, not recruitingNCT06078553Updated Nov 5, 2026

A Natural History Study in Participants With Congenital Myasthenic Syndromes (CMS) Due to Mutations in DOK7, MUSK, AGRN, or LRP4

An observational study in Congenital Myasthenic Syndrome, sponsored by argenx. Active, not recruiting at 33 sites in 12 countries. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by argenx · Observational

Updated Nov 5, 2026Now Active, not recruitingPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
152
Ages
2 Years and older
Sex
All
01

Study summary

Participants will attend up to 4 study visits to collect clinical assessments. The assessments will evaluate participants' symptoms and quality of life to understand disease activity in patients with CMS due to mutations in DOK7, MUSK, AGRN, or LRP4.

More information can be found here: https://clinicaltrials.argenx.com/cms

02

Conditions studied

  • Congenital Myasthenic Syndrome
03

In context

Lead sponsor

argenx is the lead sponsor of 87 studies on the registry; 28 are open to participants now.

Of its 22 completed or terminated interventional studies of FDA-regulated products, 16 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Participants with CMS due to mutations in DOK7, MUSK, AGRN, or LRP4 receiving standard of care at their treating physician

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Can understand the requirements of the study and can provide written /assent, and willingness and ability to comply with the study protocol procedures
  • Is male or female and aged ≥2 years at the time of providing informed consent/assent
  • Has a diagnosis of CMS due to biallelic pathogenic mutations in DOK7 or any pathogenic mutations in MUSK, AGRN, or LRP4
  • Has a total Quantitative Myasthenia Gravis (QMG) score of ≥3 (applies only to participants aged ≥6 years)
  • For participants taking oral beta agonists (eg, albuterol, salbutamol, ephedrine), participant must have been receiving the medication for ≥3 months before screening/baseline

Exclusion criteria

Exclusion Criteria:

  • Known medical condition that would interfere with an accurate assessment of CMS, in the investigator's opinion
  • Is currently participating in any interventional clinical study with a study drug at the time of providing /assent
  • Diagnosis of CMS due to mutation of any gene other than DOK7, MUSK, AGRN, or LRP4
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
152 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Summary statistics of retrospective and prospective collection of data on diagnosis.

    Time frame: Up to 12 months

  2. Summary statistics of retrospective and prospective collection of data on health care utilization.

    Time frame: Up to 12 months

  3. Summary statistics of retrospective and prospective collection of data on medications.

    Time frame: Up to 12 months

  4. Summary statistics of retrospective and prospective collection of data on change in health status related to CMS

    Time frame: Up to 12 months

Secondary outcomes

  1. Change from baseline for QMG total score, each component score, and raw values

    The Quantitative Myasthenia Gravis (QMG) consists of 13 items that assess ocular, bulbar, and limb function. Six of the 13 items are timed endurance tests measured in seconds. Each item has a possible score from 0 to 3, with 3 being the most severe. The total possible score is 39, with higher scores indicating more severe impairments.

    Time frame: Up to 12 months

  2. Change from baseline for MG-ADL total score

    The Myasthenia Gravis Activities of Daily Living (MG-ADL) is an 8-item scale that assesses MG symptoms and their effects on daily activities. The 8 items are rated by the participant on a scale of 0 to 3. The total score can range from 0 to 24, with higher total scores indicating more impairment.

    Time frame: Up to 12 months

  3. Change from baseline for PROMIS-GHS

    The Patient-Reported Outcomes Measurement Information System Global Health Scale (PROMIS-GHS) is a quality-of-life questionnaire that comprises questions on overall physical health, physical function, pain, and fatigue (GPH); and quality of life, mental health, satisfaction with social activities, and emotional problems (GMH). The participant marks their response on a 5-point Likert scale, with lower scores indicating poorer health

    Time frame: Up to 12 months

  4. Change from baseline for PROMIS-DFL

    The Patient-Reported Outcomes Measurement Information System Dyspnea Functional Limitations (PROMIS-DFL) is a questionnaire that evaluates the impact of dyspnea on the ability to perform daily activities within the last 7 days. The participant marks their response on a 4-point scale (0 to 3), with lower values indicating less functional impairment.

    Time frame: Up to 12 months

  5. Change from baseline for EQ-5D-5L

    The EQ-5D-5L questionnaire is a standardized test recognized by many health authorities as a generic measure of health status for clinical and economic appraisal. The descriptive system comprises 5 dimensions: mobility, self-care, usual activities, pain/discomfort, anxiety/depression. Participants mark their health status from 0 (the worst health you can imagine) to 100 (the best health you can imagine).

    Time frame: Up to 12 months

  6. Change from baseline for 3TUG

    The Triple Timed Up and Go (3TUG) is an objective measure of mobility requiring 3 repetitions (laps) to assess lower extremity weakness and fatigability.

    Time frame: Up to 12 months

  7. Change from baseline for Neuro-QoL Fatigue score

    The Quality of Life in Neurological Disorders (Neuro-QoL) Fatigue questionnaire will be completed by participants aged ≥18 years. The Neuro-QoL Pediatric Fatigue questionnaire will be completed by pediatric participants aged ≥12 to \<18 years. Participants aged \<8 years will be evaluated using the proxy version of the questionnaire.

    Time frame: Up to 12 months

07

Study locations

33 sites
08

References and documents

Related links

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Feb 2024 (actual). Primary completion is estimated for Sep 2027, 43 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 5, 2026: primary completion Jun 2027 → Sep 2027 and completion Jun 2027 → Sep 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2023
First posted
Oct 12, 2023
StartActual
Feb 13, 2024
Primary completionEst.
Sep 2027was Jun 2027
CompletionEst.
Sep 2027was Jun 2027
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Nov 5, 2026
Sites
1 site added
Show site
  • Mayo Clinic · Rochester, United States
Sep 25, 2026
Primary completion
Jun 2027→Sep 2027
Nov 5, 2026
Study completion
Jun 2027→Sep 2027
Nov 5, 2026
Enrollment
100 (estimated)→152 (actual)
Nov 5, 2026
Show all 2 updates
  1. Nov 5, 2026
    Recruiting→Active, not recruiting
    Primary completion Jun 2027→Sep 2027
    Study completion Jun 2027→Sep 2027
    Enrollment 100 (estimated)→152 (actual)
    + 3 other changes: verification date, contact details and site details
  2. Sep 25, 2026
    1 site added
    Show site
    • Mayo Clinic · Rochester, United States

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06078553
Lead sponsor
argenx
Responsible party
Sponsor
First posted
Oct 12, 2023
Start date
Feb 13, 2024
Primary completion
Sep 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Nov 5, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion